MVTG revenue from Alstom deal

New Post Public Reply Private Reply Replies (0) Message Board
Ecomike Ecomike #41
$MVTG is already drawing revenue from Alstom. Which from my estimates is now cash going into the bank the current quarter at about $75,000/month, from work done and billed the prior quarter.

The MVTG accounting/auditor is a bit wonky, and leaves much to be desired IMHO as to how he reports this stuff (even though MVTG paid for and invested BIG $$$$$s in the MVTG patents and research, and even though the market value of the patents is in the 9 figure area (easily well over $100 MM), the auditor expensed the entire costs and valued them at ZERO, which is way too one sided IMHO). They are not even listed as assets yet, even though the patents are now issued. That is just insane nonsense, but that is the screwy GAPP nonsense we got stuck with.....Ecomike rant cont...... So the money Alstom is paying MVTG, I consider to be revenue. But here are the details.

Here is how it works. Alstom, per the MVTG SEC filings, agreed to pay MVTG 150% of the cost of the MVTG lab personnel costs (hourly salary). MVTG has 6 PhDs working full time on the MVTG staff, that are some of the top, in the world, fuel cell electrochemical engineers in the field of formic acid fuel cells, and the electro-reduction of Carbon Dioxide, CO2, to formic acid.

Alstom wanted to clear the field of any remaining R&D ideas for improving the MVTG fuel cell and ERC reactor that converts CO2 to formic acid, before ramping up the funding and building of the MVTG ERC pilot plant package at the Lafarge cement plant in Canada. LaFarge is providing the pilot plant site and some funding as is Alstom (about $1,000,000 by my count), and the Canadian government $-? pending), which has already funded parts of the MVTG technology development recently and funded it before MVTG bought the technology that was government funded initially at UBC University under my friend Professor Colin Oloman.

[color=red]So back to the revenue question[/color],

[b][color=red]Alstom agreed to pay MVTG 150% of the hourly rate for the R&D staff, which in my book is a customer paying revenue to a research firm at a 50% gross profit margin, to earn a stake in the results of the lab work[/color][/b]. Also MVTG is getting the remaining R&D done with out dilution!!!

So, while I have no idea how the bean counter/auditor that MVTG is stuck with will list the revenue, it is POSITIVE cash flow with a 50% margin over cost that is cleaning up the remaining R&D to optimize the Pilot plant design and testing at the MVTG-LaFarge Pilot plant, before it is built. There are already 3 issued patents, with many more expected to be issued and filed for and announced this year, many may be announced in January.

We have reason to believe the MVTG-LaFarge Pilot plant construction will start in Feb, and be built by Noram, one of the top electrochemical reactor design and build firms in the world. Noram has already been hired, paid nearly $250,000 for completing and delivering the final pilot plant design, that was all reported in 2013 filings.

Once the full scale plant design (not the PP, the full sized plant) is completed using data from the pilot plant, Alstom and Noram will design and build it at the Lafarge plant for Lafarge at LaFarge's expense, and MVTG will earn license revenue from every ton of CO2 converted into formic acid. Formic acid prices in recent years have been as high as $1500/ton. Lafarge has many of these plants world wide!!!! They are one of the largest in the world, and Alstom has other major cement manufacturing customers worldwide already, and Alstom has many power plant customers in 100 countries world wide, power plants that Alstom designed and built, that want to make a revenue producing product out of their CO2 emissions as well, before carbon taxes kill their profits. Power plants their pollution control is a key segment of world wide Alstom sales.

The MVTG Pilot plant will be mobile, and will be used for multiple site demos, such as coal fired power plants, and steel mills.

High Wire Networks Inc. (HWNI) Stock Research Links

HWNI Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

UWM Faces Class Action Deadline: Key Insights for Investors

Updated Category News Views 3

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

Continue Reading
Surfing Dogs Ride Waves, Support Orphan Pets

Updated Category News Views 3

Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...

Continue Reading
First-Time Homeowners: Unseen Pitfalls of Insurance

Updated Category News Views 6

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...

Continue Reading
Trial Disappointment: No Significant Gains in NSCLC

Updated Category News Views 21

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

Continue Reading
MRI Surveillance Gains Ground in Lung Cancer Care

Updated Category News Views 7

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

Continue Reading
PwC US and India Unite for Global Consultancy Powerhouse

Updated Category News Views 7

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

Continue Reading
Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Updated Category News Views 6

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

Continue Reading
PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

Updated Category News Views 6

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

Continue Reading
Ris-Rez May Set New Standard in Relapsed SCLC

Updated Category News Views 7

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

Continue Reading
GORGIE Unleashes Berry Burst: Target's New Drink Star

Updated Category News Views 6

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

Continue Reading

Top 5 Most Recently Viewed Articles

AIP Realty Trust Announces Successful Non-Brokered Offering

Updated Category News Views 177

AIP Realty Trust's Financial Milestone Achieved AIP Realty Trust has made waves in the investment community by successfully finalizing the initial tranche of a significant non-brokered private placement. These efforts have brought in an impressive total of 7,260,000 Preferred Units—Series B Convertible, valued at US$0.50 each, resulting in gross proceeds of...

Continue Reading
Medtronic's BrainSense™ Receives CE Marking for Parkinson's Care

Updated Category News Views 499

Medtronic’s Innovative Approval for Parkinson's Treatment Medtronic plc (NYSE: MDT), a global leader in healthcare technologies, has achieved a significant milestone by receiving CE Mark approval for its BrainSense™ Adaptive deep brain stimulation (aDBS) system and the BrainSense™ Electrode Identifier (EI). This remarkable advancement introduces the world's first...

Continue Reading
Understanding the New Rating for abrdn Asia-Pacific Income Fund

Updated Category News Views 84

KBRA's Rating Insights on abrdn Asia-Pacific Income Fund Recently, KBRA has taken significant steps by assigning a new rating to the Series B Mandatory Redeemable Preferred Shares (MRPS) of abrdn Asia-Pacific Income Fund, Inc. (NYSE: FAX). This rating stands at 'AA-', illustrating the organization's confidence in the stability and security of these investment instruments....

Continue Reading
Protect Your Investment: Join the Applied Therapeutics Class Action

Updated Category News Views 156

Understanding the Class Action for Applied Therapeutics Investors As an investor in Applied Therapeutics, Inc. (APLT), you may have felt the financial impact of recent challenges the company has encountered. The firm is currently facing a class action lawsuit aimed at addressing securities fraud that adversely affected investors between specific dates. This situation is...

Continue Reading
Heritage Capital Group Facilitates Mittauer's Strategic Sale

Updated Category News Views 205

Heritage Capital Group Facilitates Mittauer's Strategic Sale Heritage Capital Group, Inc. ("Heritage"), a respected investment banking and financial advisory firm known for serving middle-market and emerging growth companies, has successfully guided its client, Mittauer & Associates, Inc. ("Mittauer"), through a significant transition in its business landscape. This...

Continue Reading